Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.

Kohei HagiwaraTakashi MatsukiTakuro OkadaChihiro FushimiTakahito KondoHideaki TakahashiIsaku OkamotoKunihiko TokashikiKenji HanyuTakuma KishidaTatsuya ItoGai YamashitaKiyoaki TsukaharaTatsuo MasubuchiYuichiro TadaKaho MomiyamaRyohei YaguchiNobuhiko OridateG O OmuraTaku Yamashita

Published in: Anticancer research (2024)

Pre-treatment NLR, PLR, CALLY index, and mGPS might be predictive markers of survival in patients with R/M SCCHN treated with pembrolizumab.

Keyphrases

advanced non small cell lung cancer
small cell lung cancer
squamous cell carcinoma
combination therapy
epidermal growth factor receptor
replacement therapy